ESMO 2024: BMS scores with ES-SCLC drug in patients with brain metastases
Bristol Myers Squibb’s (BMS) lung cancer monoclonal antibody BMS-986012 has nearly doubled overall survival (OS) in patients with extensive-stage small …
Post
-
-
Charting the road to operational success in clinical trials
At the upcoming 12th Annual Outsourcing in Clinical Trials Nordics meeting, experts from the pharmaceutical, biotechnology and medical device industries, …
-
Oncternal stock crashes by 60% as it lays off staff and scraps trials
Oncternal Therapeutics’s stock has slumped after the company announced it is dropping its clinical trials and will lay off staff …
-
World Sepsis Day 2024: need remains for improved trial design and targeted drugs
World Sepsis Day, which takes place annually on 13 September, aims to raise awareness of the devastating condition that claims …
-
EASD 2024: GLP-1R agonists treatment improves glucose control and reduces bodyweight in type 1 diabetes patients
In the last couple of days at the European Association for the Study of Diabetes (EASD) 60th Annual Meeting 2024, …
-
Is light to moderate alcohol consumption a risk for dementia?
Modifiable risk factors for dementia such as heavy alcohol consumption, have been documented from previous research studies. However, the relationship …
-
Polio vaccination campaign begins in Gaza in response to current outbreak
The World Health Organization confirmed on 4 September that over 187,000 children in Gaza under the age of ten had …
-
Kine Sciences doses first subject in Phase Ib/IIa CIDP treatment trial
Kine Sciences has dosed the first subject in its Phase Ib/IIa clinical trial of KINE-101, a new nano peptide aimed …
-
Bright Minds Biosciences launches Phase II trial of absence epilepsy treatment
Bright Minds Biosciences has announced the commencement of the Phase II BREAKTHROUGH clinical trial of BMB-101, targeting adult patients with …
-
Alio starts trial to expand label for remote monitoring device
US-based Alio plans to increase the use case for its wearable remote monitoring SmartPatch technology to monitor health metrics in …
-
ESMO: Moderna’s mRNA solid tumour vaccine shows early promise
Moderna’s mRNA cancer vaccine for solid tumours shows early signs of promise in interim data from a Phase I study. The …
-
Neurocrine’s Phase II schizophrenia trial fails to meet primary endpoint
Neurocrine Biosciences has reported that its Phase II ERUDITE clinical trial of luvadaxistat did not achieve its primary endpoint in …
-
GSK reports positive interim data from mRNA influenza vaccine trial
GSK has reported positive interim results from its Phase II trial of mRNA-based multivalent influenza vaccine candidate, GSK4382276A. The trial, which …
-
Alzheimer’s heterogeneity necessitates diverse enrollment in clinical trials
Clinical trials are the final bridge to cross before a new treatment can reach patients. Though Alzheimer's disease affects individuals …
-
Gilead’s twice-yearly lenacapavir outperforms Truvada in men
Gilead has unveiled positive topline results from an interim analysis of its Phase III PURPOSE 2 trial showing that its …
